One patient, a 46 - year old woman, started the trial with stage 4 ovarian cancer — which generally has a very poor prognosis — following five prior courses of chemotherapy. (sciencedaily.com)
He'd already been on multiple courses of chemotherapy, but his disease showed few signs of improvement. (sciencemag.org)